Skip to main content

Fiscal Wizard · Single-issue tearsheet

NEUP / Jun 22, 2026 Run #7655

NEUP

Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.

Composite verdict

F 27.0 / 100
Bearish setup · Trend Following 16 drivers · 3 gates blocking
  • ADX DI Cross
  • Volume Climax
  • Vortex Signal
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 194th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 21 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from
Asset value $3.52Earnings power value $0.75Price $4.31

Priced above its no-growth earnings power value ($0.75/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

53.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 100
Free Cash Flow Yield 0
Asset Turnover 100
EPS Growth (YoY) 0
Return on Assets 82
Operating Margin 25

Technicals Bearish

0.0 / 100

Bearish setup leads (ADX DI Cross, Volume Climax, Vortex Signal); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 11
Vortex Signal 11
Trendline Break 12

Risk Gates

3 blocking 5 caution

3 guards active, 19 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for NEUP.